In this January 2023 CBD industry roundup, Leafly reports on shifting regulatory and market signals, including Google’s partial rollback of its CBD advertising ban, early indications of forthcoming FDA regulation, and international developments such as France legalizing hemp flower. The article also highlights independent testing that exposed widespread CBD mislabeling in gummies, reinforcing concerns about product quality and oversight. Within this broader context, Vitality CBD is featured for its full-spectrum tincture, positioned as a standards-driven product amid growing scrutiny of safety, labeling accuracy, and manufacturing practices.